Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

Orion-konsernin tilinpäätöstiedote tammi–joulukuu 2025

View original at globenewswire.com
Orion-konsernin tilinpäätöstiedote tammi–joulukuu 2025 ORION OYJ TILINPÄÄTÖSTIEDOTE 1–12/2025 12.2.2026 klo 12:00 Orion-konsernin tilinpäätöstiedote tammi–joulukuu 2025 Loka–joulukuu 2025 lyhyesti Liikevaihto oli 695,3 miljoonaa euroa (434,4 miljoonaa euroa 10–12/2024)Liikevoitto oli 328,1 (92,7) miljoonaa euroaLaiment…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 revenue expected to be 1,900-2,100 million EUR

    80% confidence

  • Nubeqa has repeatedly exceeded expectations

    80% confidence

  • Orion's performance was very strong in 2025 with solid financial results and clear progress in strategy implementation

    80% confidence

  • Generics and Consumer Health sales expected to be at same level or slightly higher than 2025

    80% confidence

  • No material change expected in total investment volume in 2026 compared to 2025

    80% confidence

  • Sales and marketing expenses expected to increase in 2026

    80% confidence

  • Orion's booked annual Nubeqa sales have potential to exceed 1 billion EUR by end of current decade

    80% confidence

  • Animal Health business unit expected to grow slightly in 2026

    80% confidence

  • Q4 2025 was a strong quarter that was a great ending to successful year 2025

    80% confidence

  • ODM-212 and its mechanism of action have significant potential in different indications

    80% confidence

  • Expects another very strong year in 2026 with continued work building wellbeing and Orion's future

    80% confidence

  • Company aims to expand ODM-212 phase 2 program during 2026

    80% confidence

  • Orion's booked Nubeqa royalties and product sales expected to grow significantly in 2026

    80% confidence

  • Branded Products business unit expected to grow in 2026 with respiratory diseases therapy area and Easyhaler portfolio as growth drivers

    80% confidence

  • 2026 operating profit expected to be 550-750 million EUR

    80% confidence

  • R&D expenses expected to increase in 2026 compared to 2025

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com